Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 9/20 | 0.59 |
| ▸ | RARB | P10826 | 9/20 | 0.59 |
| ▸ | RARG | P13631 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382630 | 0.85 | RARG (0.79) | RARARARBRARGPDK2 | |
| SCHEMBL382277 | 0.85 | RARA (0.66) | RARARARBRARGPDK2 | |
| SCHEMBL381907 | 0.85 | RARA (0.66) | RARARARBRARGPDK2CYP1A2 | |
| SCHEMBL11888308 | 0.82 | RARG (0.63) | RARARARBRARGNPSR1MAPT | |
| SCHEMBL381823 | 0.82 | RARG (0.63) | RARARARBRARGNPSR1MAPT | |
| SCHEMBL382273 | 0.81 | RARG (0.64) | RARARARBRARGMAPTPDK2 | |
| SCHEMBL381755 | 0.80 | RARG (0.68) | RARARARBRARGMAPTPDK2 | |
| SCHEMBL382166 | 0.78 | RARB (0.64) | RARARARBRARGALDH1A1MAPT | |
| SCHEMBL382210 | 0.78 | RARB (0.57) | RARARARBRARGPDK2 | |
| SCHEMBL382587 | 0.77 | RARA (0.80) | RARARARBRARGALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470871-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-11 | — | — | US | disclosed |
| US-8227507-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-1831149-B1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2012-01-25 | — | — | EP | disclosed |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-18 | — | — | US | disclosed |
| US-7807708-B2 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
| EP-1831149-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066978-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | RARA 2/4885RARB 1/4885RARG 3/4885 |
| US-20120258996-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | RARA 2/4885RARB 1/4885RARG 3/4885 |
| US-20100292296-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS | RARB, RARA, RARG | RARA 2/4885RARB 1/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.